Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ Other — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
DARZALEX
$3.96B+22.5%
SPINE,SPORTS & OTHER
$2.85B-2.5%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
RYBREVANT + LAZCLUZE
$257M+82.3%
Tecvayli
$202M+33.8%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

Aebi Schmidt Holding AG logo
AEBIOther — Sales
$114.02M+10.1%
Goodyear Tire & Rubber Company logo
GTOther — Net Sales (Note 2)
$4M-42.9%
Suncoke Energy logo
SXCOther — Sales and other operating revenue
$1.3M-35.0%
La-Z-Boy logo
LZBOther — Sales
$63.58M+33.8%
ECV
ECVTOther — Sales
$8.19M+2.6%
Intrepid Potash logo
IPIOther — Sales
$17K-78.8%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's other — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's other — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported other — sales to customers (note 9) of $2.9B in Q1 2026.
How has Johnson & Johnson's other — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's other — sales to customers (note 9) increased by 2.1% year-over-year, from $2.84B to $2.9B.
What is the long-term trend for Johnson & Johnson's other — sales to customers (note 9)?
Over 4 years (2021 to 2025), Johnson & Johnson's other — sales to customers (note 9) has grown at a 21.5% compound annual growth rate (CAGR), from $1.68B to $3.66B.
What does other — sales to customers (note 9) mean?
This metric represents the total revenue generated from product lines or business activities categorized as 'Other' within the company's segment reporting. It captures income streams that do not fall under the primary reporting segments, providing visibility into diversified or emerging business units. Monitoring this figure helps investors understand the contribution of non-core operations to the overall top-line performance.